Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation; a Japanese multicenter experience.

about

Interaction of immunosuppressants with HCV antivirals daclatasvir and asunaprevir: combined effects with mycophenolic acid

P2860

Q58754930-ADF85ED8-1FC0-49ED-805D-78DE76495B0A

P2860

Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation; a Japanese multicenter experience.

Item

http://www.wikidata.org/entity/Q40053650

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Asunaprevir and daclatasvir fo ...... panese multicenter experience.

@en

type

Item

label

Asunaprevir and daclatasvir fo ...... panese multicenter experience.

@en

prefLabel

Asunaprevir and daclatasvir fo ...... panese multicenter experience.

@en

P1476

Asunaprevir and daclatasvir fo ...... panese multicenter experience.

@en

P2093

Akihiko Soyama

http://www.w3.org/2001/XMLSchema#string

Akinobu Taketomi

http://www.w3.org/2001/XMLSchema#string

Hideaki Okajima

http://www.w3.org/2001/XMLSchema#string

Hideki Ohdan

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Furukawa

http://www.w3.org/2001/XMLSchema#string

Kaori Kuramitsu

http://www.w3.org/2001/XMLSchema#string

Kohei Ishiyama

http://www.w3.org/2001/XMLSchema#string

Masahiro Shinoda

http://www.w3.org/2001/XMLSchema#string

Mitsuo Shimada

http://www.w3.org/2001/XMLSchema#string

Nobuhisa Akamatsu

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.

New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir.

Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens.

Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1.

Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment.

Asunaprevir/daclatasvir and sofosbuvir/ledipasvir for recurrent hepatitis C following living donor liver transplantation.

Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.

Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism.

Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice.

P31

scholarly article

P356

10.1111/CTR.13109

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28881052

http://www.w3.org/2001/XMLSchema#string

P921

liver transplantation

Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation; a Japanese multicenter experience.

about

P2860

P2860

Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation; a Japanese multicenter experience.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P31

P356

P433

P478

P50

P577

P698

P921